A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies with ALX-0061

Trial Profile

A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies with ALX-0061

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2016

At a glance

  • Drugs Vobarilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Ablynx
  • Most Recent Events

    • 07 Jul 2016 Results from this trial are expected in 2018, according to an Ablynx media release.
    • 19 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top